Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years

Mao Hu, Azadeh Shoaibi, Yuhui Feng, Patricia C. Lloyd, Hui Lee Wong, Elizabeth R. Smith, Kandace L. Amend, Annemarie Kline, Daniel C. Beachler, Joann F. Gruber, Mahasweta Mitra, John D. Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N. McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Richard Forshee, Steven A. Anderson
doi: https://doi.org/10.1101/2023.10.13.23296903
Mao Hu
1Acumen LLC, Burlingame, CA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: patricia.lloyd{at}fda.hhs.gov
Azadeh Shoaibi
2US Food and Drug Administration, Silver Spring, MD, USA
PhDMHS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhui Feng
1Acumen LLC, Burlingame, CA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia C. Lloyd
2US Food and Drug Administration, Silver Spring, MD, USA
PhDScM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Lee Wong
2US Food and Drug Administration, Silver Spring, MD, USA
PhDMSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Smith
1Acumen LLC, Burlingame, CA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kandace L. Amend
3Optum Epidemiology, Boston, MA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annemarie Kline
4Carelon Research, Wilmington, DE, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Beachler
5CVS Health/Aetna, Blue Bell, PA, USA
PhDMPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joann F. Gruber
2US Food and Drug Administration, Silver Spring, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahasweta Mitra
1Acumen LLC, Burlingame, CA, USA
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Seeger
3Optum Epidemiology, Boston, MA, USA
DrPHPharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlalynn Harris
4Carelon Research, Wilmington, DE, USA
MPHPhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Secora
6IQVIA, Falls Church, VA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce Obidi
2US Food and Drug Administration, Silver Spring, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Wang
1Acumen LLC, Burlingame, CA, USA
BA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Song
3Optum Epidemiology, Boston, MA, USA
MAMURP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl N. McMahill-Walraven
4Carelon Research, Wilmington, DE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Reich
6IQVIA, Falls Church, VA, USA
MDPhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rowan McEvoy
1Acumen LLC, Burlingame, CA, USA
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rose Do
1Acumen LLC, Burlingame, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoganand Chillarige
1Acumen LLC, Burlingame, CA, USA
MPA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Clifford
3Optum Epidemiology, Boston, MA, USA
MSBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle D Cooper
4Carelon Research, Wilmington, DE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Forshee
2US Food and Drug Administration, Silver Spring, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Anderson
2US Food and Drug Administration, Silver Spring, MD, USA
PhDMPP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials.

Objective To conduct near real-time monitoring of health outcomes following COVID-19 vaccination in the United States (US) pediatric population aged 6 months to 17 years.

Design We evaluated 21 pre-specified health outcomes; 15 were sequentially tested through near real-time surveillance, and 6 were monitored descriptively within a cohort of vaccinated children. We tested for increased rate of each outcome following vaccination compared to a historical comparator cohort.

Setting This population-based study was conducted under the US Food and Drug Administration public health surveillance mandate using three commercial claims databases.

Participants Children aged 6 months to 17 years were included if they received a monovalent COVID-19 vaccine dose before early 2023 and had continuous enrollment in a medical health insurance plan from the start of an outcome-specific clean window to the COVID-19 vaccination dose.

Exposure Exposure was defined as receipt of a monovalent BNT162b2, mRNA-1273, or NVX-CoV2373 COVID-19 vaccine dose. The primary analysis evaluated dose 1 and dose 2 combined, and secondary analyses evaluated each dose separately. Follow-up time was censored at death, disenrollment, end of risk window, end of study period, or a subsequent dose administration.

Main Outcomes Twenty-one prespecified health outcomes.

Results The study included 4,102,016 enrollees aged 6 months to17 years. Thirteen of 15 outcomes sequentially tested did not meet the threshold for a statistical signal. In the primary analysis, myocarditis or pericarditis signals were detected following BNT162b2 vaccine in children aged 12-17 years old and seizures/convulsions signals were detected following vaccination with BNT162b2 and mRNA-1273 in children aged 2-4/5 years. However, in a post-hoc sensitivity analysis, the seizures/convulsions signal was sensitive to background rates selection and was not observed when 2022 background rates were selected instead of 2020 rates.

Conclusions and Relevance Of the two signaled outcomes, the myocarditis or pericarditis signals are consistent with previously published reports. The new signal detected for seizures/convulsions among younger children should be further investigated in a robust epidemiological study with better confounding adjustment.

Competing Interest Statement

Annemarie Kline, Cheryl McMahill-Walraven, Djeneba Audrey Djibo worked on grants, subcontracts, or contracts from Harvard Pilgrim Health Care Institute, Brown University (National Institute on Aging/ IMPACT Collaboratory), Reagan Udall Foundation for the FDA, Academy of Managed Care pharmacy's Biologics and Biosimilar Collective Intelligence Consortium (BBCIC), TherapeuticsMD, Reachnet (Louisiana Public Health Institute), IQVIA, Pfizer, Carelon Research (formerly Healthcore), and Patient Centered Outcomes Research Institute as employees of CVS Health and report stock or stock options from CVS Health; Carelon Research; Kandace Amend, Robin Clifford, John Seeger, and Jennifer Song reports stock or stock options in UnitedHealth Group; Daniel C. Beachler is an employee of Carelon Research who has previously contracted with Pfizer Inc. for separate projects. No other authors report relevant disclosures.

Clinical Protocols

https://bestinitiative.org/wp-content/uploads/2022/12/C19-Active-Monitoring-Protocol-Addendum-2022.pdf

Funding Statement

The US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. The Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDA's Sentinel Initiative.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The study protocol was publicly posted previously and a brief report was published describing the preliminary results of BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years on JAMA Pediatrics, as referenced in the manuscript. Data analyses and related documents can be made available where needed, by contacting the corresponding author. De-identified participant data will not be shared without approval from the data partners.

https://covid.cdc.gov/covid-data-tracker

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 15, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
Mao Hu, Azadeh Shoaibi, Yuhui Feng, Patricia C. Lloyd, Hui Lee Wong, Elizabeth R. Smith, Kandace L. Amend, Annemarie Kline, Daniel C. Beachler, Joann F. Gruber, Mahasweta Mitra, John D. Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N. McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Richard Forshee, Steven A. Anderson
medRxiv 2023.10.13.23296903; doi: https://doi.org/10.1101/2023.10.13.23296903
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
Mao Hu, Azadeh Shoaibi, Yuhui Feng, Patricia C. Lloyd, Hui Lee Wong, Elizabeth R. Smith, Kandace L. Amend, Annemarie Kline, Daniel C. Beachler, Joann F. Gruber, Mahasweta Mitra, John D. Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N. McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Richard Forshee, Steven A. Anderson
medRxiv 2023.10.13.23296903; doi: https://doi.org/10.1101/2023.10.13.23296903

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pediatrics
Subject Areas
All Articles
  • Addiction Medicine (432)
  • Allergy and Immunology (758)
  • Anesthesia (221)
  • Cardiovascular Medicine (3306)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5165)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3280)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1196)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4939)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (729)
  • Orthopedics (283)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (545)
  • Pediatrics (1303)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7520)
  • Radiology and Imaging (1709)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)